Recent studies have converged on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopaminergic communication. While GCGR stimulators are widely employed for managing type 2 diabetes, their emerging effects on reinforcement circuits, specifically mediated by dopaminergic pathw